Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.
Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A. Raab MS, et al. Among authors: breitkreutz i. Cancer Res. 2012 Oct 15;72(20):5374-85. doi: 10.1158/0008-5472.CAN-12-2026. Epub 2012 Aug 31. Cancer Res. 2012. PMID: 22942257
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM; HOVON; GMMG. Goldschmidt H, et al. Among authors: breitkreutz i. Ann Hematol. 2003 Oct;82(10):654-9. doi: 10.1007/s00277-003-0685-2. Epub 2003 Jul 4. Ann Hematol. 2003. PMID: 12845480 Clinical Trial. No abstract available.
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Tai YT, et al. Among authors: breitkreutz i. Cancer Res. 2005 Dec 15;65(24):11712-20. doi: 10.1158/0008-5472.CAN-05-1657. Cancer Res. 2005. PMID: 16357183
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, Cremer FW, Lowenthal RM, Huesing J, Fruehauf S, Moehler T, Ho AD, Goldschmidt H. Klaus J, et al. Among authors: breitkreutz i. Eur J Haematol. 2007 Jan;78(1):21-8. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2895.x. Epub 2006 Sep 28. Eur J Haematol. 2007. PMID: 17042762
29 results